ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Zacks Dec 3 09:35 ET

Esperion Announces New Drug Submissions in Canada for NEXLETOL (Bempedoic Acid) and NEXLIZET (Bempedoic Acid and Ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

GlobeNewswireDec 2 08:00 ET

Express News | Esperion Therapeutics Inc - No Serious Adverse Events Observed in Bempedoic Acid Trial

ReutersNov 26 08:00 ET

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

GlobeNewswireNov 26 08:00 ET

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

GlobeNewswireNov 21 08:00 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 19 06:31 ET · Ratings